Payer Dynamics in Hep C Market Begin to Level Out
NEWS March 11, 2015
View at Gilead in a 6 month -to one year time frame. We KNOW there is a ton of misinfo floating around and, for some reason, bogus info seems to move this stocki. I'm refraing from buying more options or using margin.
I'm in the 3 year followup study for ION 3 clinical trial..(i was cured in 8 weeks 1 1/2 years ago). I talk with and listen to the hepatoligists currently conducting the curred stage 3 trial for the pangenic hep c cure.
They are quite upset about express scripts/abbvie issue (these docs are not gilead employees). Thye feel that express scripts, not themselves, should have the liability if patient is injured due to a Rx forced upon the docs for abbv product.. They say the "liver" societies, etc are taking a strong stance against against this forced Rx.
The fight here is only beginning.
I urge skittish investors to take a long term outlook. This fight is just beginning....and it's at its worst in the US.
Look at the big positive that every day Gilead can buyback not more that 25 % of the days volume....this is giving precious time to GILD to execute all of its buyback it can at around $100. At last conf call that was $18 billion....that ~180 million shares at $100.....that 12% of the float!!!
I think its 46% off list price as opposed to the 22% off list offerec in 2014. That would put a 12 tx at over $50K
Notice that no one is attempginb go make a generic pak of viekira....
Do u think they should do away with patents and copyrights?
In India, for example, a pill can cost only $10, with a 24-week treatment costing about $1,800, the company has said. Such tiered pricing is available in 91 countries around the world.
The doctors group has criticized the voluntary licensing deals, saying that the agreements are anti-competitive and that 49 million hepatitis C patients in 50 middle-income countries are stuck in a sort of drug-access purgatory — too poor to afford the drug, too rich to get discounts.
Gilead Under Fire Again Over New Hepatitis C Program
By Jacob Batchelor
Law360, New York (March 20, 2015, 2:23 PM ET) -- Doctors Without Borders has said a plan by Gilead Sciences to require patients in developing countries to show residency and identity documents, ostensibly to halt the flow of discounted hepatitis C medication into richer countries, will only block life-saving access to vulnerable populations.
Gilead seeks to put in place a system that requires patients receiving discounted treatment in many developing countries to present national identification and residency papers in an effort to halt the black market flow of cheap versions of the drug to more developed nations, where a three-month course can cost $84,000, the international nonprofit said.
You can get the answer to that with just a little research.....hint...look up doctors without borders complaint against Gilead
startin last august.....coiling for a breakout one way or the other.... i hope up
they are selling at ~ $1.....hmm ..
Public reimbursement comes after a positive recommendation from the Common Drug Review, and as a result of a productive collaboration between Gilead Canada and the Pan-Canadian Pharmaceutical Alliance (pCPA) to ensure participating provinces are able to provide timely access to patients in need of curative treatment. This review, co-led by the BC Ministry of Health and the Ontario Ministry of Health and Long-Term Care, resulted in an agreement with member provinces to fund the innovative therapy for patients.
the press is really deficient in good news for Gilead ...thatr plays well for buybacks.... nothing will counter high tx levels and high earnings.
We utilized $5.3 billion in cash to repurchase 59 million shares at an average price of $90.29 per share in 2014. In the fourth quarter, we utilized $2 billion of the May 2014 $5 billion share repurchase plan.""
The more time that GILD has to buyback at $100 or less the better off we sharholders are...GILD has no concern about rebutting selloff on bogus news...
Amiadarone was approved in 1985..... gee do ya think there are better drugs now....You cant take Amiadarone with Abbvie tx either....so who cares.... ? Abbvie has a long list of drug interactions yet that seems of little concern. Do u think someone is going to invent a new drug to accomodate those on Amiadarone.... ??? What is the value of this news to stockholders??
there is link to drug interactions with amiadaron
with Amiadaron. Those are 322 drugs that cannot be used with amiadaron...doesn't Abbivie have Ritonavir?
It's a continuation of certain press dissing Gilead... Works to our atvantage because of buyback opportunity.
The bottom line will be the number of prescriptions written for Gilead products. In the mean time, these press sources just lose credibility over time.
I understand your frustration but u need to take a longer term view.....Gilead is not "hot" now but its forming a very nice consolidating triangle. . I encourage you to pull up 3, 4 and 5 year charts. This stock is risky for options this early in the year. The proof will be the earniings/trx numbers as the year goes on. The management is anxious to buy back as much stock as they can at reasonable prices. This in contrast to other buybacks that are often done just to push a stock up. So kick back and know this languishing of GILD share price facilitates buyback effortrs.